Table 2 Subgroup analysis of infarct volume

Randomisation

0.28

Yes

13

165

-2.13(-2.81, -1.45)

49

23.63(0.02)

No

8

84

-2.94(-4.26, -1.62)

53

14.81(0.04)

Blinding

0.26

Yes

7

156

-1.95(-2.82, -1.08)

51

12.21(0.06)

No

14

116

-2.65(-3.49, -1.80)

51

26.29(0.02)

Animal species

0.47

SD rat

14

121

-2.66(-3.71, -1.62)

53

27.60(0.01)

C57BL/6J mice

5

78

-2.16(-3.04, -1.29)

47

7.57(0.11)

Source of EVs

0.78

MSC

10

137

-2.36(-3.27, -1.45)

66

26.50(< 0.01)

NSC

4

64

-1.94(-2.84, -1.04)

27

4.08(0.25)

Blood

5

34

-2.83(-4.36, -1.31)

11

4.52(0.34)

Soma

2

28

-2.47(-5.33, 0.39)

39

1.65(0.20)

Methods of engineered

0.66

Transfection

12

146

-2.34(-3.05, -1.64)

45

18.22(0.05)

Coculture

5

73

-2.05(-3.24, -0.85)

65

11.42(0.02)

Ultrasonic

3

18

-4.49(-9.79, 0.81)

51

4.12(0.13)

Engineering targets

0.20

Cell

10

123

-1.92(-2.71, -1.13)

53

19.28(0.02)

EVs

9

86

-2.85(-4.02, -1.67)

39

13.04(0.11)

Route of administration

0.54

IV

15

177

-2.57(-3.73, -1.78)

53

29.62(< 0.01)

Transcranial

4

58

-2.11(-3.37, -0.86)

56

6.81(0.36)

Timepoint of administration

0.58

Pretreatment

2

26

-2.53(-4.92, -0.14)

28

1.38(0.24)

0-24 h

12

174

-2.20(-2.89, -1.52)

51

22.23(0.02)

25-72 h

3

29

-2.00(-4.43, 0.43)

54

4.34(0.11)

Multiple

4

34

-3.20(-4.48, -1.93)

0

2.11(0.55)